A Study of Revaree Plus in People With Breast Cancer

Inclusion Criteria:

* ≥18 years of age at the time of signing informed consent.
* Stage 0-3 hormone-receptor positive breast cancer confirmed at MSKCC
* Able to complete study questionnaires in English or Spanish
* Breast cancer patients must have completed primary therapy (surgery, and/or chemotherapy, and/or radiation therapy) or currently on maintenance therapy
* Currently on an aromatase inhibitor or tamoxifen or Selective Estrogen Receptor Modulators (SERM)
* Currently have no clinical evidence of disease
* Reporting being bothered by vaginal symptoms of estrogen deprivation (i.e., vaginal dryness, dyspareunia, or discomfort \[pain with intercourse or examination\])
* A total score of 4 or greater in VAS
* Without history of other cancers (excluding non-melanoma skin cancer)
* Must sign an informed consent indicating that the participant understands the purpose of, and procedures required for the study and is willing to participate in the study

Exclusion Criteria:

* Inability to provide informed consent
* Vaginal bleeding of unknown etiology within 12 months of study entry
* Currently taking hormone replacement therapy \[local or systemic\] (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)
* Existing use of external estrogens or nonhormonal moisturizers (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)
* No known allergies to any ingredients in 10mg HLA suppository